Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

Benzinga05:06

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

GlobeNewswire05:05

Iridex CEO Patrick Mercer Joins Board of Directors

TipRanksNov 26 19:31

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And Wll Be Effective For Services Performed After Nov. 17

BenzingaNov 19 21:20

Express News | IRIDEX Corp: Encouraged That Transscleral Cyclophotocoagulation Remains Unaffected by Recent Glaucoma Lcd

BreakingsNov 19 21:16

Express News | IRIDEX Corp: IRIDEX's Cyclo G6 Product Family Is Unaffected by New Reimbursement Limitations

BreakingsNov 19 21:14